Chronic Lymphocytic Leukemia Clinical Trial
MEOI and HRQoL in CLL Patients Treated With BTKis
Summary
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in leukemia-cll/" >chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US).
Eligibility Criteria
Inclusion Criteria:
≥18 years old
Physician-confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
BTKi naïve patients who initiate acalabrutinib or ibrutinib treatment alone or in combination with an anti-CD20 mAb within 7 days (before or after) study enrollment*. Both treatment naïve and relapsed/refractory CLL patients will be included.
Provides informed consent
Adequate English reading skills
Able to access and use a computer, tablet, or smartphone to complete PROs
Exclusion Criteria:
Use of BTKi any time prior to study enrollment.
Currently receiving systemic treatment for another malignancy
Currently enrolled in a clinical trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 16 Locations for this study
Fountain Valley California, 92708, United States
Redlands California, 92373, United States
Boca Raton Florida, 33486, United States
Fort Lauderdale Florida, 33308, United States
Saint Petersburg Florida, 33709, United States
Tallahassee Florida, 32308, United States
Tamarac Florida, 33321, United States
Tampa Florida, 33705, United States
Savannah Georgia, 31405, United States
Honolulu Hawaii, 96813, United States
Jackson Mississippi, 39202, United States
Berkeley Heights New Jersey, 07922, United States
Amherst New York, 14228, United States
Charlotte North Carolina, 27103, United States
Philadelphia Pennsylvania, 19111, United States
York Pennsylvania, 17403, United States
How clear is this clinincal trial information?